Hematologic Oncology | Specialty

Checkpoint Inhibition May Improve CAR T-Cell Persistence

December 2nd 2018

Checkpoint inhibition showed promise for augmenting or extending response to chimeric antigen receptor T-cell therapy in some patients with relapsed B-cell acute lymphoblastic leukemia.

Daratumumab Safe and Effective When Added to VRd in Newly Diagnosed MM

December 2nd 2018

Daratumumab added to bortezomib, lenalidomide, and dexamethasone induced at least a very good partial response in all patients and a stringent complete response or CR in 63% of patients at the end of consolidation therapy in the run-in phase of an open-label study of transplant-eligible patients with newly diagnosed multiple myeloma.

Dr. Ravandi on BiTE Antibody AMG 330 Data in Relapsed/Refractory AML

December 2nd 2018

Farhad Ravandi, MBBS, professor of medicine, department of leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase I first-in-human study of AMG 330, an anti-CD33 bispecific T-Cell engager (BiTE) antibody construct, in patients with relapsed/refractory acute myeloid leukemia (AML) during the 2018 ASH Annual Meeting.

Dr. Phillips on Activity With Acalabrutinib Plus Bendamustine/Rituximab in MCL

December 2nd 2018

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses safety and efficacy findings for acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma (MCL) during the 2018 ASH Annual Meeting.

Luspatercept Reduces Blood Transfusion Dependence in Lower-Risk MDS Anemia

December 2nd 2018

Treatment with luspatercept significantly reduced the need for frequent red blood cell transfusions in nearly 53% of patients with anemia associated with low- to intermediate-risk myelodysplastic syndrome.

Reduced Treatment Equally Effective in DLBCL

December 2nd 2018

Treating younger patients with low-risk diffuse large B-cell lymphoma with 2 fewer frontline cycles of R-CHOP greatly reduced toxicity without sacrificing efficacy, according to findings from the FLYER trial.

Tisagenlecleucel Benefit Sustained in DLBCL Follow-Up

December 2nd 2018

Tisagenlecleucel continued to demonstrate durable objective response rates with a median of 19 months of follow-up for patients with relapsed or refractory diffuse large B-cell lymphoma, according to updated findings from the phase II JULIET study.

Tisagenlecleucel OS, RFS Sustained in Long-Term Follow-Up for Pediatric ALL

December 2nd 2018

Treatment with the CD19-targeted CAR T-cell therapy tisagenlecleucel demonstrated sustained rates of relapse-free survival and overall survival at 24 and 18 months for pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia.

Ibrutinib Established as Standard for Older CLL Patients

December 2nd 2018

Ibrutinib as monotherapy and combined with rituximab significantly improved progression-free survival compared with bendamustine plus rituximab as frontline therapy for older patients with chronic lymphocytic leukemia.

ASH 2018: Dr. O'Connor Shares Insight on MCL and T-Cell Lymphoma Advances

December 1st 2018

ASH 2018: Dr. Wierda Discusses Pivotal Updates in CLL

December 1st 2018

ASH 2018: Dr. Landgren Highlights Pivotal Myeloma Data

December 1st 2018

Dr. Mesa Discusses Exciting Abstracts on Myeloproliferative Neoplasms

December 1st 2018

Dr. Pagel Highlights the Top Abstracts From the 2018 ASH Annual Meeting

December 1st 2018

Dr. Raje Discusses Investigational Treatment Strategies in Multiple Myeloma

December 1st 2018

Dr. Desai Discusses Advances in Treatment for Patients With AML

December 1st 2018

OncLive News Network On Location: In San Diego Monday, December 3

December 1st 2018

OncLive News Network On Location: In San Diego Sunday, December 2

December 1st 2018

OncLive News Network On Location: In San Diego Saturday, December 1

December 1st 2018

New Hairy Cell Leukemia Therapy Aims to Produce Complete Remissions

November 30th 2018

Robert J. Kreitman, MD, discusses key attributes of moxetumomab pasudotox and its potential impact in hairy cell leukemia.